| 经肝动脉栓塞化疗治疗结肠癌肝转移患者临床初步研究* |
| |
| 引用本文： | 王保信,邢宏建. 经肝动脉栓塞化疗治疗结肠癌肝转移患者临床初步研究*[J]. 实用肝脏病杂志, 2017, 20(6): 744-747. DOI: 10.3969/j.issn.1672-5069.2017.06.026 |
| |
| 作者姓名： | 王保信 邢宏建 |
| |
| 作者单位： | 065000河北省廊坊市 中国石油天然气集团公司中心医院肿瘤科 |
| |
| 摘 要： | 目的 探讨肝动脉栓塞化疗（TACE）治疗结肠癌肝转移患者的临床效果。方法 2013年11月~2014年11月于中国石油天然气集团公司中心医院诊治的结肠癌肝转移患者90例,被随机等分为观察组45例和对照组45例。两组均接受TACE治疗,只是观察组在治疗过程中应用雷替曲塞灌注。常规检测血清CA19-9和CEA水平。结果 观察组近期临床治疗总有效率为51.1%,显著高于对照组的22.2%（P<0.05）;两组患者治疗前血清CA19-9和CEA水平比较差异无统计学意义（P>0.05）,治疗后3月两组上述肿瘤指标均有明显降低,观察组血清CA19-9和CEA水平分别为（18.46± 7.59） U/ml和（3.52± 2.58） ng/ml,明显低于对照组的【（27.65± 11.85） U/ml和（9.86± 3.47） ng/ml,P<0.05】;观察组不良反应发生率为22.2%,显著低于对照组的46.7%（P<0.05）;观察组1 a、2 a、3 a生存率分别为88.9%、73.3%、57.8%,明显高于对照组的66.7%、42.2%、33.3%（P<0.05）。结论 TACE术中应用雷替曲塞灌注治疗结肠癌肝转移患者可有效提高近期和远期临床治疗效果,在临床治疗上具有一定的参考意义。*基金项目:廊坊市科学技术研究与发展计划项目（编号：2014013021）作者单位：065000河北省廊坊市 中国石油天然气集团公司中心医院肿瘤科第一作者：王保信,男, 41岁,医学硕士,主治医师。E-mail:xhjxing@163.com
|
| 关 键 词： | 肝转移癌 肝动脉栓塞化疗 雷替曲塞 治疗 |
| 收稿时间： | 2017-04-12 |
Preliminary clinical study on transcatheter arterial chemoembolization in patients with liver metastasis from colon-rectal cancer |
| |
| Wang Baoxin,Xing Hongjian. Preliminary clinical study on transcatheter arterial chemoembolization in patients with liver metastasis from colon-rectal cancer[J]. Journal of Clinical Hepatology, 2017, 20(6): 744-747. DOI: 10.3969/j.issn.1672-5069.2017.06.026 |
| |
| Authors: | Wang Baoxin Xing Hongjian |
| |
| Affiliation: | Department of Oncology,Central Hospital,Oil and Gas Group Co., LTD, China, Langfang 065000,Hebei Province |
| |
| Abstract: | 【Abstract】 Objective To explore the clinical efficacy of transcatheter hepatic arterial embolization （TACE） in treatment of patients with liver metastasis from colon-rectal cancer. Methods90patients with liver metastasis from colon-rectal cancer in our hospital between November2013, November2014were recruited, and they were randomly divided into observation group, control group. The patients in both groups were treated with TACE, and the only difference was arterial infusion of raltitrexed in the observation group. Clinical efficacy, serum CA19-9, CEA levels, adverse events, long-term survival rates were observed, recorded in the two groups. Results The total effective rate in the observation group was51.1%, significantly higher than22.2% in the control group（P<0.05）;before treatment, there were no significant differences as respect to serum CA19-9, CEA levels between the two groups （P>0.05）, while three months after treatment, serum CA19-9, CEA levels in the observation group were （18.46±7.59） U/ml, （3.52±2.58） ng/ml, significantly lower than [（27.65±11.85） U/ml and（9.86±3.47） ng/ml, respectively, in the control group, P<0.05];the incidence of adverse reactions was22.2% in the observation group, significantly lower than46.7% in the control group （P<0.05）;the1a, 2a, 3a survival rates in the observation group was88.9%, 73.3%, 57.8%, respectively, obviously higher than66.7%, 42.2%, 33.3% in the control group （P<0.05）. Conclusion The application of raltitrexed in TACE treatment of patients with liver metastasis from colon-rectal cancer can effectively improve patients' clinical efficacy, prolong the long-term survivals |
| |
| Keywords: | Liver metastasis Transcatheter hepatic arterial embolization Raltitrexed Therapy |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《实用肝脏病杂志》浏览原始摘要信息 |
|
点击此处可从《实用肝脏病杂志》下载免费的PDF全文 |
|
